Clinical trial
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
NCT00246402 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00246402 |
|---|---|
| Title | Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV |
| Official title | Anti-Lipolytic Strategy for HIV Lipodystrophy |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Acipimox |
| Enrollment | 30 |
| Start date | Sep 1, 2002 |
| Completion | Aug 1, 2006 |
| First posted | Oct 31, 2005 |
| Last update posted | May 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: